Prostate cancer (PCa) is the most frequently diagnosed cancer and the second leading cause of cancer death among men in developed countries.([@b1]) Most patients are initially responsive to androgen-deprivation therapy (ADT), but their cancers eventually become resistant to ADT and progress to castration-resistant prostate cancer (CRPC). CRPC is difficult to treat, and most clinical trials for advanced PCa have shown limited benefits, with disease progression and metastasis to the skeleton or other sites.([@b2],[@b3]) Therefore, understanding the molecular mechanisms of CRPC and the metastatic pathways underlying PCa using genomic approaches would help to prevent and improve therapies for the disease.

The discovery of non-coding RNAs (ncRNAs) in the human genome was an important conceptual breakthrough in the post-genome sequencing era.([@b4]) Improved understanding of ncRNAs is necessary for continued progress in cancer research. MicroRNAs (miRNAs) are endogenous small ncRNA molecules (19--22 bases in length) that regulate the expression of protein-coding genes by repressing translation or cleaving RNA transcripts in a sequence-specific manner.([@b5]) Currently, 2578 human mature miRNAs are registered at miRBase release 20.0 (<http://microrna.sanger.ac.uk/>). miRNAs are unique in their ability to regulate multiple protein-coding genes. Bioinformatic predictions indicate that miRNAs regulate \>30--60% of the protein-coding genes in the human genome.([@b6],[@b7])

A significant amount of evidence suggests that miRNAs are aberrantly expressed in many human cancers and that they play significant roles in the initiation, development and metastasis of those cancers.([@b8],[@b9]) Some highly expressed miRNAs can function as oncogenes by repressing tumor suppressors, whereas low-level miRNAs can function as tumor suppressors by negatively regulating oncogenes. It is believed that normal regulatory mechanisms can be disrupted by the aberrant expression of tumor-suppressive or oncogenic miRNAs in cancer cells. Therefore, identification of aberrantly expressed miRNAs is an important first step toward elucidating miRNA-mediated oncogenic pathways.

Based on the foregoing discussion, we have constructed miRNA expression signatures using PCa clinical specimens and investigated the roles of miRNAs in PCa oncogenesis using differentially expressed miRNAs.([@b10]) Recently, we demonstrated that several miRNAs were downregulated in cancer tissues and that *miR-1*, *miR-133a*, *miR-143* and *miR-145* functioned as tumor suppressors by targeting several oncogenic genes.([@b11],[@b12]) Based on our PCa miRNA signature, *miR-218* was significantly downregulated, suggesting that this miRNA might be a candidate tumor suppressor in PCa cells. The aim of the present study was to investigate the functional significance of *miR-218* in cancer cells and to identify novel *miR-218*-regulated genes that contributed to PCa oncogenesis and metastasis.

We found that restoration of mature *miR-218* inhibited cancer cell migration and invasion, directly targeting LIM and SH3 protein 1 (*LASP1*). Downregulating the *LASP1* significantly inhibited cell migration and invasion by cancer cells. Furthermore, *LASP1*-regulated novel molecular pathways were investigated through the use of si-*LASP1*-treated cells. Tumor-suppressive *miR-218*-*LASP1*-mediated cancer pathways might provide new insights into the potential mechanisms of PCa oncogenesis and metastasis.

Materials and Methods
=====================

Clinical prostate specimens
---------------------------

Seventeen radical prostatectomy specimens were obtained from patients with PCa who underwent treatment at Chiba University Hospital (Chiba, Japan) from 2009 to 2013. Seventeen paired samples of PCa and corresponding normal tissues were used for the present study. The samples considered normal were free of cancer cells as determined by pathologic examination. The patients' backgrounds and clinico-pathological characteristics are summarized in Table [1](#tbl1){ref-type="table"}. Before tissue collection, all patients provided written informed consent of tissue donation for research purposes. The protocol was approved by the Institutional Review Board of Chiba University.

###### 

Patients' characteristics

  No.   PCa or non-PCa   Age   PSA (ng/mL)   Gleason score   Stage   TNM classification       
  ----- ---------------- ----- ------------- --------------- ------- -------------------- --- ---
  1     PCa              64    5.4           3 + 4           C       3a                   0   0
  2     PCa              68    12.8          3 + 5           C       3a                   0   0
  3     PCa              70    16.1          4 + 5           C       3b                   0   0
  4     PCa              69    25.8          4 + 5           B       2a                   0   0
  5     PCa              64    29.9          4 + 3           B       2b                   0   0
  6     PCa              61    7.9           3 + 4           C       3a                   0   0
  7     PCa              68    8.8           4 + 5           B       2b                   0   0
  8     PCa              66    6.1           4 + 3           B       2b                   0   0
  9     PCa              70    11.8          4 + 4           C       3b                   0   0
  10    PCa              60    22.1          3 + 4           B       2b                   0   0
  11    PCa              70    8.9           3 + 4           B       2a                   0   0
  12    PCa              72    4.5           3 + 4           B       2b                   0   0
  13    PCa              56    7.1           3 + 4           C       3a                   0   0
  14    PCa              65    13.1          4 + 3           B       2b                   0   0
  15    PCa              65    9.5           4 + 4           B       2b                   0   0
  16    PCa              65    5.8           4 + 3           B       2a                   0   0
  17    PCa              65    4.6           5 + 4           B       2b                   0   0
  1     Non-PCa                                                                               
  2     Non-PCa                                                                               
  3     Non-PCa                                                                               
  4     Non-PCa                                                                               
  5     Non-PCa                                                                               
  6     Non-PCa                                                                               
  7     Non-PCa                                                                               
  8     Non-PCa                                                                               
  9     Non-PCa                                                                               
  10    Non-PCa                                                                               
  11    Non-PCa                                                                               
  12    Non-PCa                                                                               
  13    Non-PCa                                                                               
  14    Non-PCa                                                                               
  15    Non-PCa                                                                               
  16    Non-PCa                                                                               
  17    Non-PCa                                                                               

Cell culture and RNA extraction
-------------------------------

PC3 and DU145 cells, human PCa cells obtained from the American Type Culture Collection (Manassas, VA, USA), were maintained in RPMI-1640 medium supplemented with 10% FBS in a humidified atmosphere of 5% CO~2~ and 95% air at 37°C.

Total RNA was isolated from formalin-fixed paraffin-embedded (FFPE) samples with four 5-μm thick slices, using the miRNeasy FFPE Kit (Qiagen, Hilden, Germany) according to the manufacturer\'s protocol. RNA quality was confirmed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).

Quantitative real-time RT-PCR
-----------------------------

The procedure for PCR quantification was described as previously.([@b11]--[@b13]) The TaqMan probes and primers for *LASP1* (P/N: Hs01078815_m1 \[Applied Biosystems, Foster City, CA, USA\]) and for *GUSB* (the internal control; P/N: Hs00939627_m1 \[Applied Biosystems\]) were assay-on-demand gene expression products. The expression levels of *miR-218* (Assay ID: 000521 \[Applied Biosystems\]) were analyzed by TaqMan quantitative real-time PCR (TaqMan MicroRNA Assay \[Applied Biosystems\]) and normalized to the expression of *RNU48* (Assay ID: 001006 \[Applied Biosystems\]). All reactions were performed in triplicate, and each assay included negative control reactions that lacked cDNA.

Transfections with mature microRNA and siRNA
--------------------------------------------

The following mature miRNA species were used in the present study: mature miRNA, Pre-miR miRNA Precursor (has-*miR-218*; P/N: AM17100 \[Applied Biosystems\]). The following siRNAs were used: Stealth Select RNAi siRNA, *si-LASP1* (P/N: HSS105970 \[Invitrogen, Carlsbad, CA, USA\]) and negative control miRNA/siRNA (P/N: AM17111 \[Applied Biosystems\]). RNAs were incubated with OPTI-MEM (Invitrogen) and Lipofectamine RNAiMax reagent (Invitrogen) as described previously. The transfection efficiencies of miRNA in PC3 and DU145 cells were confirmed based on downregulation of *TWF1* (*PTK9*) mRNA following transfection with *miR-1* as previously reported.([@b13])

Cell proliferation, migration and invasion assays
-------------------------------------------------

Cells were transfected with 10 nM miRNA or siRNA by reverse transfection and plated in 96-well plates at 3 × 10^3^ cells per well. After 72 h, cell proliferation was determined with the XTT assay using a Cell Proliferation Kit II (Roche Molecular Biochemicals, Mannheim, Germany) as previously reported.([@b14],[@b15]) Cell migration was evaluated with a wound healing assay. Cells were plated in 6-well plates, and the cell monolayers were scraped using a P-20 micropipette tip. The initial gap length (0 h) and the residual gap length 24 h after wounding were calculated from photomicrographs.

A cell invasion assay was carried out using modified Boyden chambers containing Transwell membrane filter inserts (precoated with Matrigel) with 8 μm pores in 24-well tissue culture plates (BD Biosciences, Bedford, MA, USA) at 2 × 10^5^ cells per well. Cells were transfected with 10 nM miRNA or siRNA by reverse transfection and plated in 10-cm dishes at 8 × 10^5^ cells per dish. After 48 h, the cells were collected, and 2 × 10^5^ cells were added to the upper chamber of each migration well.

Cells were allowed to invade for 48 h. After gentle removal of the non-migratory cells from the filter surface of the upper chamber, the cells that invaded into the lower chamber were fixed and stained with Diff-Quick (Sysmex Corporation, Kobe, Japan). The number of cells that migrated to the lower surface was determined microscopically by counting four areas of constant size per well. All experiments were performed in triplicate.

Western blotting
----------------

Cells were harvested 72 h after transfection, and lysates were prepared. 50 μg protein lysates were separated on Mini-PROTEAN TGX Gels (Bio-Rad, Hercules, CA, USA) and transferred to PVDF membranes. Immunoblotting was performed with mouse anti-LASP1 antibodies (1:250; HSA012072 \[Sigma-Aldrich, St Louis, MO, USA\]); anti-GAPDH antibodies (1:1000; ab8245 \[Abcam, Cambridge, UK\]) were used as an internal loading control.

Screening of *miR-218* and *LASP1* target genes using *in silico* analysis and gene expression data
---------------------------------------------------------------------------------------------------

Genes regulated by *miR-218* were listed using the TargetScan database as described previously.([@b14],[@b15]) To investigate the expression status of candidate *miR-218*-target genes in PCa clinical specimens, we examined gene expression profiles in the Gene Expression Omnibus (GEO) database (accession number: GSE29079). In addition, we performed gene expression analysis using *miR-218*-transfected PC3 cells and *si-LASP1*-transfected PC3 cells compared to control transfection cells. Oligo-microarray Human 60K (Agilent Technologies) was used for gene expression studies. Microarray procedures and data mining methods were as described previously.([@b14],[@b15])

Molecular pathway analysis using Kyoto Encyclopedia of Genes and Genomes pathways
---------------------------------------------------------------------------------

To identify molecular signaling pathways regulated by *miR-218* or *LASP1* in PCa cells, *in silico* and gene expression data were adapted to Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways categories by the GENECODIS program (<http://genecodis.dacya.ucm.es>). The strategy of the analysis procedure was described previously.([@b12])

Plasmid construction and dual-luciferase reporter assay
-------------------------------------------------------

Partial wild-type sequences of the *LASP1* 3′-UTR or those with a deleted *miR-218* target sites (positions 686-692, 1587-1593 and 2080-2087 of the *LASP1* 3′-UTR) were inserted between the XhoI--PmeI restriction sites in the 3′-UTR of the hRluc gene in the psiCHECK-2 vector (C8021 \[Promega, Madison, WI, USA\]). The protocol for vector construction was as described previously.([@b16]) The synthesized DNA was cloned into the psiCHECK-2 vector. PC3 cells were transfected with 50 ng of the vector and 10 nM *miR-218* using Lipofectamine 2000 (Invitrogen). The activities of firefly and *Renilla* luciferases in cell lysates were determined with a dual-luciferase assay system (E1910 \[Promega\]). Normalized data were calculated as the ratio of *Renilla*/firefly luciferase activities.

Immunohistochemistry
--------------------

A total of 17 radical prostatectomy specimens were used (Table [1](#tbl1){ref-type="table"}). Tissue specimens were immunostained following the manufacturer\'s protocol with the UltraVision Detection System (Thermo Scientific, Fremont, CA, USA). Primary rabbit polyclonal antibodies against LASP1 (Sigma-Aldrich) were diluted 1:500. The slides were treated with biotinylated goat antibodies.

###### 

Candidate of putative *miR-218* target genes

  Entrez gene ID   Symbol     Gene name                                                                                       Location      Fold change   miR-218 transfectant   Conserved sites   Poorly conserved sites
  ---------------- ---------- ----------------------------------------------------------------------------------------------- ------------- ------------- ---------------------- ----------------- ------------------------
  5652             PRSS8      Protease, serine, 8                                                                             16p11.2       1.58          −2.08                  0                 1
  7163             TPD52      Tumor protein D52                                                                               8q21          1.52          −2.22                  2                 1
  5591             PRKDC      Protein kinase, DNA-activated, catalytic polypeptide                                            8q11          1.43          −1.88                  0                 2
  22858            ICK        Intestinal cell (MAK-like) kinase                                                               6p12.1        1.41          −2.28                  2                 1
  10983            CCNI       Cyclin I                                                                                        4q21.1        1.39          −1.56                  0                 1
  8871             SYNJ2      Synaptojanin 2                                                                                  6q25.3        1.39          −1.77                  0                 1
  5054             SERPINE1   Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1   7q22.1        1.38          −2.56                  0                 1
  23051            ZHX3       Zinc fingers and homeoboxes 3                                                                   20q12         1.33          −1.74                  0                 3
  85414            SLC45A3    Solute carrier family 45, member 3                                                              1q32.1        1.32          −1.50                  1                 0
  80195            TMEM25     Transmembrane protein 254                                                                       10q22.3       1.31          −2.01                  1                 0
  9342             SNAP29     Synaptosomal-associated protein, 29 kDa                                                         22q11.21      1.30          −1.91                  0                 1
  9289             GPR56      G protein-coupled receptor 56                                                                   16q13         1.30          −2.23                  0                 1
  6745             SSR1       Signal sequence receptor, alpha                                                                 6p24.3        1.30          −1.63                  1                 0
  3927             LASP1      LIM and SH3 protein 1                                                                           17q11-q21.3   1.28          −1.96                  1                 2
  54443            ANLN       Anillin, actin binding protein                                                                  7p15-p14      1.26          −1.82                  0                 1
  1824             DSC2       Desmocollin 2                                                                                   18q12.1       1.25          −2.33                  0                 1
  10447            FAM3C      Family with sequence similarity 3, member C                                                     7q31          1.24          −1.92                  1                 0
  79443            FYCO1      FYVE and coiled-coil domain containing 1                                                        3p21.31       1.24          −1.62                  1                 0
  4008             LMO7       LIM domain 7                                                                                    13q22.2       1.22          −1.75                  1                 0
  272              AMPD3      Adenosine monophosphate deaminase 3                                                             11p15         1.22          −1.57                  0                 1
  9725             TMEM63A    Transmembrane protein 63A                                                                       1q42.12       1.21          −1.64                  0                 1
  9917             FAM20B     Family with sequence similarity 20, member B                                                    1q25          1.21          −1.63                  1                 1
  114908           TMEM123    Transmembrane protein 123                                                                       11q22.1       1.19          −1.69                  1                 0
  5781             PTPN11     Protein tyrosine phosphatase, non-receptor type 11                                              12q24         1.17          −1.50                  1                 0
  5175             PECAM1     Platelet/endothelial cell adhesion molecule 1                                                   17q23.3       1.16          −1.89                  0                 2
  23788            MTCH2      Mitochondrial carrier 2                                                                         11p11.2       1.16          −2.28                  0                 2
  79071            ELOVL6     ELOVL fatty acid elongase 6                                                                     4q25          1.15          −2.30                  0                 1
  6645             SNTB2      Syntrophin, beta 2 (dystrophin-associated protein A1, 59 kDa, basic component 2)                16q22.1       1.15          −2.34                  1                 1
  10613            ERLIN1     ER lipid raft associated 1                                                                      10q24.31      1.14          −1.62                  0                 1
  112939           NACC1      Nucleus accumbens associated 1, BEN and BTB (POZ) domain containing                             19p13.2       1.14          −1.63                  2                 0
  54902            TTC19      Tetratricopeptide repeat domain 19                                                              17p12         1.14          −1.74                  0                 1
  55604            LRRC16A    Leucine rich repeat containing 16A                                                              6p22.2        1.13          −2.29                  0                 1
  26420            MAPK9      Mitogen-activated protein kinase 9                                                              11            1.13          −1.51                  0                 1
  9497             SLC4A7     Solute carrier family 4, sodium bicarbonate cotransporter, member 7                             3p22          1.12          −1.95                  0                 1
  10186            LHFP       Lipoma HMGIC fusion partner                                                                     13q12         1.12          −1.79                  2                 0
  66008            TRAK2      Trafficking protein, kinesin binding 2                                                          2q33          1.10          −1.67                  0                 1
  54621            VSIG10     V-set and immunoglobulin domain containing 10                                                   12q24.23      1.09          −2.06                  1                 2
  357              SHROOM2    Shroom family member 2                                                                          Xp22.3        1.08          −1.78                  0                 2
  41               ACCN2      Acid-sensing (proton-gated) ion channel 1                                                       12q12         1.08          −1.51                  1                 0
  3248             HPGD       Hydroxyprostaglandin dehydrogenase 15-(NAD)                                                     4q34-q35      1.02          −2.54                  1                 1

Statistical analysis
--------------------

The relationships between two groups and the numerical values obtained by real-time RT-PCR were analyzed using the paired *t*-test. The relationship among three variables and numerical values was analyzed using the Bonferroni-adjusted Mann--Whitney *U*-test. All analyses were performed using Expert StatView software (version 4; SAS Institute, Cary, NC, USA).

Results
=======

Expression levels of *miR-218* in prostate cancer specimens and cell lines
--------------------------------------------------------------------------

To validate our past miRNA profiling results, we evaluated the expression levels of *miR-218* in 17 radical prostatectomy specimens. Quantitative stem-loop RT-PCR demonstrated that *miR-218* expression was significantly lower in clinical PCa specimens and PCa cell lines (PC3 and DU145) compared with non-cancerous specimens (Fig. [1](#fig01){ref-type="fig"}). The typical FFPE specimens used for expression analysis in this study are shown in [Fig. S1](#SD1){ref-type="supplementary-material"}.

![The expression levels of *miR-218* in clinical specimens and prostate cancer (PCa) cell lines (PC3 and DU145). Real-time PCR showed that the expression levels of *miR-218* were significantly lower in PCa tissues and cell lines than in normal prostate tissues. *RNU48* was used as an internal control.](cas0105-0802-f1){#fig01}

Effects of restoring *miR-218* on cell proliferation, migration and invasion activities in prostate cancer cell lines
---------------------------------------------------------------------------------------------------------------------

To investigate the functional effects of *miR-218*, we performed gain-of-function studies using miRNA transfection of PC3 and DU145 cell lines.

The XTT assay demonstrated that cell proliferation was not inhibited in *miR-218* transfectants in comparison with the mock or miR-control transfectant cells (Fig. [2](#fig02){ref-type="fig"}a).

![Effects of *miR-218* transfection on prostate cancer (PCa) cell lines (PC3 and DU145). (a) Cell proliferation was determined with XTT assays 72 h after transfection with 10 nM *miR-218*, miR-control or mock transfection. (b) Cell invasion activity was determined with the Matrigel invasion assay. (c) Cell migration activity determined with the wound healing assay. \**P* \< 0.001.](cas0105-0802-f2){#fig02}

The Matrigel invasion assay demonstrated that cell invasion activity was significantly inhibited in *miR-218* transfectants in comparison with the mock or miR-control transfectant cells (Fig. [2](#fig02){ref-type="fig"}b).

The migration assay demonstrated that cell migration activity was significantly inhibited in *miR-218* transfectants in comparison with the mock or miR-control transfectant cells (Fig. [2](#fig02){ref-type="fig"}c).

Identification of candidate genes targeted by *miR-218*
-------------------------------------------------------

To gain further insight into the genes affected by *miR-218*, we analyzed a combination of *in silico* and gene expression data from PCa clinical specimens. First, we screened *miR-218-*targeted genes using the TargetScan database and identified 2940 genes. Next, we pared down the 2940 genes based on two kinds of gene expression data as follows: (i) upregulated genes determined by the gene expression dataset of PCa clinical specimens in GEO (accession number: GSE29079); and (ii) downregulated genes (log~2~ ratio \< −1.5) following *miR-218* transfection of PC3 cells.

In this selection, we narrowed down the *miR-218* target genes for the analysis from 40 genes (Table [2](#tbl2){ref-type="table"}). Five genes (*TPD52*, *ICK*, *ZHX3*, *LASP1* and *VSIG10*) were selected when we paid attention to the numbers of putative target sites of *miR-218*. Considering which genes are contributing to cancer cell migration and invasion among these five genes, we paid attention to cytoskeleton-regulated genes for control of cancer metastasis according to our previous studies.([@b13],[@b14]) As a result of *miR-218* target genes, we focused on the LIM and SH3 protein 1 (*LASP1*) gene, a cytoskeletal scaffold protein that has critical roles in cytoskeletal organization and cell migration. *LASP1* was examined in further analyses.

*LASP1* was a direct target of *miR-218* in prostate cells
----------------------------------------------------------

We performed quantitative real-time RT-PCR and western blotting in PC3 and DU145 cells to investigate whether *LASP1 gene* expression and LASP1 protein expression were reduced by restoration of *miR-218*. The mRNA and protein expression levels of *LASP1*/LASP1 were significantly repressed in *miR-218* transfectants in comparison with mock or miR-control transfectants (Fig. [3](#fig03){ref-type="fig"}a,b).

![*LASP1* expression was suppressed by *miR-218* transfection of prostate cancer (PCa) cells. (a) *LASP1* mRNA expression 72 h after transfection with *miR-218. GUSB* expression was used for normalization. (b) LASP1 protein expression 72 h after transfection with *miR-218*. GAPDH was used as a loading control. (c) *miR-218* binding sites in the 3′-UTR of *LASP1* mRNA. Luciferase reporter assays using three vectors encoding putative *miR-218* target sites at positions 686--692, 1587--1593 and 2080--2087 for both wild-type and deletion (Del). *Renilla* luciferase values were normalized to firefly luciferase values, \**P* \< 0.001.](cas0105-0802-f3){#fig03}

We performed luciferase reporter assays of PC3 to determine whether *LASP1* mRNA had target sites for *miR-218*. The TargetScan database predicted that three putative *miR-218*-binding sites existed in the 3′-UTR of *LASP1* (positions 686--692, 1587--1593 and 2080--2087 \[Fig. [3](#fig03){ref-type="fig"}c\]). We used vectors encoding either the partial wild-type sequence of the 3′-UTR of *LASP1* mRNA, including the predicted *miR-218* target sites, or "deletion" vectors; that is, those lacking the *miR-218* target sites. We found that the luminescence intensity was significantly reduced by transfection with *miR-218* and two vectors carrying the wild-type 3′-UTR of *LASP1* (positions 686--692 and 1587--1593), whereas transfection with deletion vectors (where nucleotides at positions 695--691 and 2080--2086 had been removed) blocked the decrease in luminescence (*P* \< 0.001, Fig. [3](#fig03){ref-type="fig"}c). These data suggest that *miR-218* bounds directly to two specific binding sites in the 3′-UTR of *LASP1* mRNA.

Effects of downregulating *LASP1* on cell proliferation, migration and invasion in prostate cancer cell lines
-------------------------------------------------------------------------------------------------------------

To investigate the functional role of *LASP1* in PCa cells, we performed loss-of-function studies using si-*LASP1* transfectants. First, we evaluated the knockdown efficiency of si-*LASP1* treatments in PC3 and DU145. Quantitative real-time RT-PCR and western blotting indicated that the siRNA effectively downregulated *LASP1*/LASP1 expression in both cell lines (Fig. [4](#fig04){ref-type="fig"}).

![*LASP1* mRNA and LASP1 protein expression levels were suppressed by si-LASP1 transfection of DU145 and PC3 cells. (a) *LASP1* mRNA expression 72 h after transfection with *si-LASP1*. *GUSB* expression was used for normalization. (b) LASP1 protein expression 72 h after transfection with *si-LASP1*. GAPDH was used as a loading control. The ratio of LASP1/GAPDH expression was evaluated using ImageJ software (ver. 1.43; <http://rsbweb.nih.gov/ij/index.html>).](cas0105-0802-f4){#fig04}

The XTT assay demonstrated that cell proliferation was not inhibited in *si-LASP1* transfectants in comparison with the mock or miR-control transfectant cells (Fig. [5](#fig05){ref-type="fig"}a). The Matrigel invasion assay demonstrated that cell invasion activity was significantly inhibited in *si-LASP1* transfectants in comparison with the mock or negative control transfectant cells (Fig. [5](#fig05){ref-type="fig"}b). The migration assay demonstrated that cell migration activity was significantly inhibited in *si-LASP1* transfectants in comparison with the mock or negative control transfectant cells (Fig. [5](#fig05){ref-type="fig"}c).

![Effects of *LASP1* downregulation by *si-LASP1* on PCa cells (PC3 and DU145). (a) Cell proliferation determined with the XTT assay. (b) Cell migration activity determined with the wound healing assay. (c) Cell invasion activity determined with the Matrigel invasion assay. \**P* \< 0.001.](cas0105-0802-f5){#fig05}

Immunohistochemical detection of LASP1 in prostate cancer clinical specimens
----------------------------------------------------------------------------

We determined the expression levels of LASP1 in PCa specimens by immunohistochemical staining. LASP1 was strongly expressed in several cancer lesions, whereas no or low expression was observed in normal regions (Fig. [6](#fig06){ref-type="fig"}). There was no significant correlation between LASP1 expression and various tested clinicopathological parameters (Gleason score and stages, data not shown).

![Immunohistochemical staining of LASP1 in prostate clinical specimens. Differences in LASP1 expression were observed in cancer lesions and adjacent normal prostate tissues in the same fields: (a) patient number 6; and (b) patient number 16. Overexpression of LASP1 was observed in cancer lesions. In contrast, negative staining of LASP1 in normal prostate glands and stromal tissues (left panel, original magnification ×50; right panel, original magnification ×100).](cas0105-0802-f6){#fig06}

Identification of novel molecular pathways regulated by *LASP1* in prostate cancer cells
----------------------------------------------------------------------------------------

To investigate molecular pathways regulated by LASP1, a genome-wide gene expression analysis was performed in PC3 cells. A total of 1269 genes were downregulated in *si-LASP1* transfection. Downregulated genes, both *si-LASP1*-transfectants and *miR-218*-transfectants (top 18 genes), are shown in Table [3](#tbl3){ref-type="table"}. We also assigned the downregulated genes to KEGG pathways using the GeneCodis program (<http://genecodis.cnb.csic.es>) as described previously.([@b12],[@b15]) A total of 21 pathways were identified as significantly enriched annotations (Table [4](#tbl4){ref-type="table"}). We focused on the focal adhesion pathway and the genes categorized in this pathway are listed in Table [5](#tbl5){ref-type="table"}.

###### 

Downregulated genes both *si-LASP1* and *miR-218-*transfects in PC3 cells

  Entrez gene ID   Symbol     Gene name                                                     Expression (log~2~ ratio)   
  ---------------- ---------- ------------------------------------------------------------- --------------------------- -------
  10529            NEBL       Nebulette                                                     −2.03                       −3.79
  54757            FAM20A     Family with sequence similarity 20, member A                  −2.09                       −2.93
  3131             HLF        Hepatic leukemia factor                                       −4.69                       −2.62
  1381             CRABP1     Cellular retinoic acid binding protein 1                      −1.33                       −2.60
  254552           NUDT8      Nudix (nucleoside diphosphate linked moiety X)-type motif 8   −2.57                       −2.53
  4312             MMP1       Matrix metallopeptidase 1 (interstitial collagenase)          −0.90                       −2.53
  3927             LASP1      LIM and SH3 protein 1                                         −1.96                       −2.50
  27151            CPAMD8     C3 and PZP-like, alpha-2-macroglobulin domain containing 8    −0.56                       −2.49
  3866             KRT15      Keratin 15                                                    −3.32                       −2.44
  126823           KLHDC9     Kelch domain containing 9                                     −0.99                       −2.43
  8722             CTSF       Cathepsin F                                                   −0.84                       −2.43
  128434           VSTM2L     V-set and transmembrane domain containing 2 like              0.00                        −2.35
  3339             HSPG2      Heparan sulfate proteoglycan 2                                −2.23                       −2.28
  6678             SPARC      Secreted protein, acidic, cysteine-rich (osteonectin)         −4.21                       −2.24
  10669            CGREF1     Cell growth regulator with EF-hand domain 1                   −0.78                       −2.13
  25890            ABI3BP     ABI family, member 3 (NESH) binding protein                   −2.58                       −2.12
  11093            ADAMTS13   ADAM metallopeptidase with thrombospondin type 1 motif, 13    −0.67                       −2.10
  2171             FABP5      Fatty acid binding protein 5 (psoriasis-associated)           −1.58                       −2.09

###### 

Significantly enriched KEGG pathways regulated by *si-LASP*1 in PC3 cells

  Number of genes   *P*-value   Annotations
  ----------------- ----------- -----------------------------------------------------------
  17                8E-08       (KEGG) 04512: ECM-receptor interaction
  16                7E-05       (KEGG) 04142: Lysosome
  18                0.0001      (KEGG) 05010: Alzheimer\'s disease
  15                0.0005      (KEGG) 04910: Insulin signaling pathway
  11                0.0006      (KEGG) 04146: Peroxisome
  16                0.0008      (KEGG) 04141: Protein processing in endoplasmic reticulum
  18                0.0008      (KEGG) 04510: Focal adhesion
  8                 0.001       (KEGG) 00280: Valine, leucine and isoleucine degradation
  15                0.0018      (KEGG) 00230: Purine metabolism
  9                 0.0046      (KEGG) 03320: PPAR signaling pathway
  15                0.0054      (KEGG) 05016: Huntington\'s disease
  22                0.0055      (KEGG) 05200: Pathways in cancer
  6                 0.0059      (KEGG) 00640: Propanoate metabolism
  10                0.0137      (KEGG) 05146: Amoebiasis
  6                 0.0221      (KEGG) 00480: Glutathione metabolism
  11                0.0229      (KEGG) 00190: Oxidative phosphorylation
  11                0.023       (KEGG) 05012: Parkinson\'s disease
  13                0.0266      (KEGG) 04020: Calcium signaling pathway
  8                 0.0382      (KEGG) 05222: Small cell lung cancer
  8                 0.0482      (KEGG) 05322: Systemic lupus erythematosus
  8                 0.0492      (KEGG) 05414: Dilated cardiomyopathy

KEGG, Kyoto Encyclopedia of Genes and Genomes.

###### 

Downregulated genes involved in focal adhesion pathway by *si-LASP1* transfectant in PC3 cells

  Entrez Gene ID   Gene symbol   Gene name                                                                                                                                    Expression (log~2~ ratio)   
  ---------------- ------------- -------------------------------------------------------------------------------------------------------------------------------------------- --------------------------- -------
  7791             ZYX           Zyxin                                                                                                                                        −0.64                       −0.51
  1288             COL4A6        Collagen, type IV, alpha 6                                                                                                                   −0.9                        −0.86
  3913             LAMB2         Laminin, beta 2 (laminin S) v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)   −0.53                       −0.85
  2064             ERBB2                                                                                                                                                      −0.63                       −0.91
  3675             ITGA3         Integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor)                                                                         −0.7                        −0.79
  1287             COL4A5        Collagen, type IV, alpha 5                                                                                                                   −0.45                       −0.7
  7148             TNXB          Tenascin XB                                                                                                                                  −1.18                       −1.71
  1290             COL5A2        Collagen, type V, alpha 2                                                                                                                    1.57                        −0.82
  25759            SHC2          SHC (Src homology 2 domain containing) transforming protein 2 v-akt murine thymoma viral oncogene homolog 1                                  0.72                        −0.85
  207              AKT1                                                                                                                                                       −0.52                       −0.53
  3910             LAMA4         Laminin, alpha 4                                                                                                                             0.49                        −1.07
  5881             RAC3          Ras-related C3 botulinum toxin substrate 3 (rho family, small GTP binding protein Rac3)                                                      −0.07                       −0.58
  1292             COL6A2        Collagen, type VI, alpha 2                                                                                                                   0.19                        −1.3
  1289             COL5A1        Collagen, type V, alpha 1                                                                                                                    1.34                        −0.84
  3691             ITGB4         Integrin, beta 4                                                                                                                             −0.82                       −1.17
  3912             LAMB1         Laminin, beta 1                                                                                                                              0.2                         −0.58
  7059             THBS3         Thrombospondin 3                                                                                                                             −1.2                        −1.09
  5500             PPP1CB        Protein phosphatase 1, catalytic subunit, beta isozyme                                                                                       −2.1                        −0.5

Discussion
==========

In early stage PCa, most patients initially respond to androgen deprivation therapy; however, many cases become refractory and progress to androgen-independent disease.([@b2]) Currently, there is no effective treatment for hormone-refractory PCa, with disease progression and metastasis to the skeleton or other sites.([@b3]) Thus, new approaches to effective treatments of hormone-refractory PCa are necessary.

In cancer cells, aberrant expression of miRNAs can upset the tightly regulated system of miRNA-protein-coding RNA networks. Therefore, studies of differentially expressed miRNAs in cancer cells provide important information regarding the molecular mechanisms underlying oncogenesis and metastasis. To elucidate the molecular mechanisms underlying PCa, we have examined tumor-suppressive miRNAs, focusing on their regulated molecular targets and novel cancer pathways based on PCa expression signatures.([@b10]) Our recent studies of miRNA expression signatures showed that *miR-218* was frequently reduced in other types of cancer tissues and it functioned as a tumor suppressor.([@b17]--[@b19]) Tumor-suppressive functions of *miR-218* have been described by other research groups analyzing several types of cancers.([@b20]--[@b25]) Thus, *miR-218* is a key molecule in the development of human cancers, making it important to understand the cancer molecular network that *miR-218* regulates. The molecular mechanisms of *miR-218* silencing in PCa cells are still unclear. The human genome database indicates that *miR-218* is located in two different human chromosome loci (*miR-218-1* at 4p15.31 and *miR-218-2* at 5q35.1), and these miRNAs are embedded in the intronic regions of *SLIT2* and *SLIT3*, respectively. Previous reports showed that expression of *SLIT2* and *SLIT3* were downregulated in several types of cancer cells through their promoter hypermethylation.([@b20],[@b24]) Our preliminary examination showed that downregulation of *SLIT2* and *SLIT3* were observed in primary PCa tissues ([Fig. S2](#SD2){ref-type="supplementary-material"}). Furthermore, re-expression of *SLIT2* and *miR-218* were observed after 5-aza-2′-deoxycytidine treatment of PCa cell line ([Fig. S3](#SD3){ref-type="supplementary-material"}). Thus, our data and previous studies reveal that promoter hypermethylation of *SLIT2* and *SLIT3* regions drive PCa progression and downregulation of *miR-218* in PCa cells.

To better understand PCa metastasis, we identified *miR-218* target genes using *in silico* analysis. As determined by our laboratory and others, the targets of *miR-218* include *CAV1*, *LAMB3*, *ECOP*, *IKK-B*, *PXN*, *RICTOR*, *BIRC5* and *ROBO1*.([@b17],[@b18],[@b20],[@b22]--[@b25]) Here, we focused on *LASP1*, a cytoskeletal scaffold protein. It plays critical roles in cytoskeletal organization and cell migration. *LASP1* was initially identified in a cDNA library constructed from metastasized breast cancer cells. *LASP1* encodes a LIM motif at its N-terminus and a src homology 3 (SH3) domain at its C-terminus.([@b26],[@b27]) The C-terminal SH3 domain of LASP1 functions in protein--protein interactions such as vasodilator-stimulated phosphoprotein, palladin and zyxin.([@b28]--[@b30]) Zyxin might function as a messenger in the signal transduction pathway that mediates adhesion-stimulated changes in gene expression and might also modulate the cytoskeletal organization of actin bundles.([@b30]--[@b32]) In the present study, we performed genome-wide gene expression analysis using *si-LASP1* transfectant PC3 cells to investigate LASP1-regulated molecular targets and pathways. Our data showed that zyxin was downregulated in *LASP1*-suppressed cells. Zyxin is reportedly regulated by TGF-β and contributes to the epithelial--mesenchymal transition.([@b31],[@b32]) Therefore, it will be important to analyze the molecular mechanisms of LASP1-zyxin signal transduction to better understand the metastasis of human cancer cells.

Overexpression of LASP1 has been reported in metastatic breast and ovarian cancers.([@b33],[@b34]) Our group showed that *LASP1* gene expression was elevated in bladder cancer and that downregulation of the *LASP1* gene inhibited cancer cell migration and invasion,([@b16]) suggesting that *LASP1* significantly contributes to cancer metastasis. This is the first report to show that overexpression of *LASP1* in PCa clinical tissues might be involved in the metastasis of PCa. Our previous analysis of bladder cancer showed that tumor-suppressive miRNAs such as *miR-1*, *miR-133a* and *miR-218* regulated LASP1.([@b16]) Recent studies demonstrated that LASP1 was regulated by *miR-203* in breast cancer and esophageal cancer.([@b35]--[@b37]) Immunohistchemical staining demonstrated that the overexpression of LASP1 was detected in primary PCa tissues compared with non-PCa tissues. We also measured the expression of *miR-218* status using the same FFPE tissues whether the downregulation of *miR-218* was associated with upregulation of LASP1 in PCa. Our data showed that expression of *miR-218* was significantly reduced in LASP1 overexpression PCa tissues in comparison to LASP1 low staining of non-PCa tissues ([Fig. S4](#SD4){ref-type="supplementary-material"}). Our data for primary PCa tissues and cell lines might be suggesting that downregulation of *miR-218* caused upregulation of LASP1 in PCa cells. Improved understanding of tumor-suppressive miRNAs and their regulation of *LASP1* signalling should shed light on PCa metastasis as well as delineate more effective strategies for future therapeutic interventions for this disease.

In conclusion, *miR-218* was significantly downregulated in PCa clinical specimens and appeared to function as a tumor suppressor through regulation of oncogenic *LASP1*. Elucidation of the cancer pathways and target genes regulated by the tumor-suppressive *miR-218* should provide new information on potential therapeutic targets in the treatment of PCa metastasis.
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**Fig. S1.** H&E staining of the formalin-fixed paraffin-embedded (FFPE) prostate specimens.

###### 

**Fig. S2.** Expression levels of *SLIT2*, *SLIT3* and *miR-218* in prostate cancer (PCa) tissues.

###### 

**Fig. S3.** Effects of 5-aza-2′-deoxycytidine (5-aza-dc) treatment of prostate cancer (PCa) cells.

###### 

**Fig. S4.** Expression levels of *miR-218* in prostate cancer (PCa) tissues.
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